A microbiome-personalized IBS diet held its gains for a year—but it was not a universal food list
A 12-month randomized follow-up found more durable IBS symptom relief after a microbiome-guided personalized diet than after standardized low-FODMAP advice, but the result supports a time-limited, dietitian-guided plan—not an indefinite restriction or a consumer microbiome test.
A new randomized follow-up offers a practical distinction for people with irritable bowel syndrome (IBS): a diet that is tailored to the individual may be easier to sustain than a one-size-fits-all restriction plan. But the study does not show that buying a microbiome test or avoiding FODMAPs indefinitely will solve IBS.
The same-day decision is narrower: if you have clinician-confirmed IBS and are choosing a dietary treatment, ask for a time-limited, dietitian-guided personalized plan with a six-week review rather than starting an indefinite strict low-FODMAP diet on your own. The study’s personalized plan was generated from a stool sample and a research algorithm, so the paper does not provide a food list that readers can copy at home. 1
What the study compared
The paper, published online on August 20, 2026, reports a 12-month follow-up of a randomized trial in adults aged 18–65 who met Rome IV criteria for IBS. The original trial ran across four gastroenterology clinics in Istanbul, Izmir, and Kayseri, Turkey, and was registered as NCT05646186. It randomized 149 people: 75 to a microbiome-guided personalized diet (PD) and 74 to a standard low-FODMAP diet (LFD). 23
This follow-up does not compare 149 people for a full year. It follows participants who completed the initial six-week diet intervention and its post-intervention assessment: 70 people in the PD group and 51 in the LFD group. After the six-week intervention, neither group received another prescribed dietary intervention; researchers assessed symptoms and stool samples at six and 12 months. The trial was open-label, but outcome assessors and analysts were blinded to group identity. 2
The two diets were different in kind:
- Personalized diet: Researchers used each person’s baseline gut-microbiome profile from 16S rRNA sequencing as input to a supervised machine-learning model. A search algorithm then translated the predicted microbial shifts into nutrient targets and individualized dietary recommendations.
- Low-FODMAP diet: Dietitians gave standardized advice to restrict fermentable carbohydrates known as fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. Counseling time, session structure, and frequency were matched between groups.
The PD was generated once from the baseline sample. The researchers did not repeatedly retest or re-personalize the diet during follow-up. That detail matters: the result tests whether the initial plan’s benefits lasted, not whether ongoing algorithmic adjustments are necessary or useful. 2
The symptom result was about durability
The primary symptom measure was the IBS Severity Scoring System (IBS-SSS), which runs from 0 to 500; higher scores mean more severe symptoms. A reduction of at least 50 points counted as a responder.
Both diets worked over the first six weeks. The average IBS-SSS change was −103.8 points in the PD group and −100.0 points in the LFD group, with no meaningful between-group difference at that point (p = 0.891). The interesting separation appeared later. 2
| Time point | Personalized diet | Standard low-FODMAP diet | What the comparison suggests |
|---|---|---|---|
| 6 weeks | −103.8 points | −100.0 points | Similar short-term improvement; p = 0.891 |
| 6 months | −82.0 points | −43.3 points | Some regression in the LFD group |
| 12 months | −78.3 points | +29.3 points | Between-group comparison favored PD; p = 0.001 |
A positive change means the score was higher than baseline, so the LFD group’s +29.3 points at 12 months represents a return toward—or slightly above—its starting symptom burden in this follow-up cohort. It does not mean that every person on LFD got worse.
The responder analysis gives the clearest practical scale. At 12 months, 25 of 40 PD participants (62.5%) had reduced their IBS-SSS by at least 50 points, compared with 10 of 29 LFD participants (34.5%). The absolute difference was 28.0 percentage points (95% confidence interval, 4.2 to 47.7; Fisher’s exact p = 0.029). At six weeks, the responder rates were almost identical: 72.9% versus 72.5%. 2
The follow-up also reported more favorable long-term trajectories for quality of life, anxiety, and depression in the PD group. Those secondary patterns should not be mistaken for proof that the personalized diet treats anxiety or depression; the study was designed around IBS dietary management, and the long-term sample was small. 2
The microbiome result is a clue, not the treatment outcome
The PD group showed a larger and more persistent increase in Shannon alpha diversity, a measure that combines the richness and evenness of organisms detected in a stool sample. In the PD group, the estimated increase from baseline was +0.488 at six weeks, +0.300 at six months, and +0.205 at 12 months. At 12 months, the between-group separation was statistically detectable in the model (p = 0.039 in the reported pairwise comparison).
The overall community-composition difference was much smaller. At six months, diet group explained about 3.5% of the variation in Bray–Curtis microbiome distances (R² = 0.035; p = 0.011). At 12 months, the between-group difference was no longer statistically significant (p = 0.160). The study used 16S rRNA sequencing, not direct measurement of microbial genes, enzymes, or stool metabolites. 2
So the safe reading is: the personalized diet was associated with a sustained symptom benefit and a different diversity trajectory in this cohort. The study did not prove that the diversity change caused the symptom improvement, that a higher Shannon index is automatically a healthier microbiome, or that a supplement or probiotic could reproduce the result.
Why this is not a prescription for a microbiome test
Several features keep the result in the hypothesis-generating category.
First, the 12-month analysis was restricted to people who completed the first six-week intervention. Only 40 of the 70 PD participants and 29 of the 51 LFD participants supplied 12-month clinical assessments. The authors found no statistically significant baseline or six-week differences between completers and non-completers, but those comparisons had limited power and could not rule out bias from unmeasured reasons for dropping out. The long-term follow-up was also not prospectively powered for the observed between-group contrast after attrition. 2
Second, the groups were not perfectly balanced at the start of the analyzed six-week completers. Average baseline IBS-SSS was higher in the PD group—314.4 versus 276.8 points—and stool frequency was also higher. The investigators analyzed change from baseline, but regression to the mean remains a possible contributor to a result from a small, selected follow-up cohort. 2
Third, participants knew which type of diet they were receiving. A personalized plan can produce more attention, engagement, or confidence than standardized advice even when counseling time is matched. During the year without prescribed dietary intervention, participants also reported their own adherence, antibiotic use, probiotic use, and other exposures; the study did not collect full food diaries or food-frequency questionnaires during follow-up.
Finally, the comparator was a standardized low-FODMAP intervention without continued structured reintroduction. That is not the same as the complete modern low-FODMAP pathway, which typically uses a short restriction phase followed by systematic reintroduction and personalization. The study therefore cannot establish that a carefully reintroduced low-FODMAP plan would lose its benefit in the same way.
There is also a material disclosure. ENBIOSIS Biotechnologies sponsored and funded the study, developed the AI-assisted personalized-diet model, and performed the microbiome sequencing and analyses. The corresponding author and several other authors were affiliated with the company or had a financial interest in the technology; the remaining listed authors declared no competing interests. Clinical outcomes were assessed by investigators at the participating gastroenterology centers. 2
The same-day dietary decision
If you have IBS and want to use this finding now, make the decision about process, not about a magic food list:
- Choose a six-week, dietitian-guided personalized trial that starts with your symptoms, usual diet, nutritional needs, and tolerated foods.
- Set the review date before you start. The aim is to assess symptom change and broaden the diet where possible—not to remain on an ever-narrower list.
- If low-FODMAP is the chosen first step, treat it as time-limited and plan reintroduction. Do not interpret this paper as evidence that strict restriction forever is the correct comparison.
- Do not buy a commercial microbiome test expecting this study’s result. The research algorithm, dietary translation, and clinical support were a bundled intervention, and the paper does not validate consumer testing or a universal personalized menu.
For a dietitian, the actionable takeaway is to discuss durability and reintroduction at the first visit, not only short-term symptom relief. For a person without IBS, this trial does not provide a preventive diet or a reason to alter a varied diet based on a stool-microbiome result.
The best-supported conclusion is modest but useful: personalization may help an IBS diet remain workable after the initial six weeks, but this promising signal needs a larger, independently evaluated trial before it becomes routine precision-nutrition care.
References
- 1PubMed record for the randomized follow-up
pubmed.ncbi.nlm.nih.gov
- 2Full paper in Gut Microbes
doi.org
- 3ClinicalTrials.gov registration NCT05646186
clinicaltrials.gov
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.